U.S. stocks traded higher midway through trading, with the Dow Jones index surging more than 200 points on Wednesday.the Dow traded up 0.48% to 48,673.55 while the NASDAQ rose 0.09% to 23,582.81. The S&P 500 also rose, gaining, 0.25% to 6,927.29.Check This Out: S&P 500 Hits Record Close: Investor Sentiment Improves Further, Fear Index Remains In ‘Greed’ ZoneLeading and Lagging SectorsConsumer staples shares rose by 0.7% on Wednesday.In trading on Wednesday, communication services stocks fell by 0.1%.Top Hea ...

Group 1 - UiPath Inc. will join the S&P Midcap 400, replacing Synovus Financial Corp., effective January 2, 2026, leading to a 6.8% increase in shares to $17.05 in after-hours trading [1] - Agios Pharmaceuticals Inc. received FDA approval for AQVESME™ for treating anemia in adults with alpha- or beta-thalassemia, but shares fell 1.4% to $24.59 [1] - Can Fite Biopharma announced a 1-for-3,000 reverse share split, resulting in a 28.8% drop in shares to $0.17 in after-hours trading [1] - Citius Pharmaceuticals reported a quarterly loss of 11 cents per share, better than the expected loss of 43 cents, causing shares to surge 22.1% to $1.27 [1] - Ramaco Resources announced a $100 million stock repurchase plan, leading to a 7.1% increase in shares to $18.09 in after-hours trading [1]

Financial Performance - Citius Pharmaceuticals reported a net loss of $39.7 million, or $3.38 per share, for the fiscal year ended September 30, 2025, compared to a net loss of $40.2 million, or $5.97 per share, for the previous year[6]. - Net loss for 2025 was $(39,740,269), slightly higher than $(39,425,839) in 2024[15]. - Stock-based compensation decreased to $10,836,291 from $11,839,678 year-over-year[15]. - Net cash used in operating activities improved to $(26,552,738) from $(28,201,375) in the previous year[15]. - Net cash used in investing activities increased to $(5,750,000) from $(5,000,000) in 2024[15]. - Net proceeds from common stock offerings rose significantly to $32,303,148 compared to $13,803,684 in 2024[15]. - Cash and cash equivalents stood at $4.3 million as of September 30, 2025, compared to $3.3 million in the previous year[6]. - Cash and cash equivalents at the end of 2025 were $4,252,290, up from $3,251,880 in 2024[15]. - Inventory changes resulted in a significant increase in cash outflow of $(12,649,207) compared to $(2,133,871) in 2024[15]. - Accounts payable increased to $8,766,481 from $1,999,877 year-over-year, indicating improved supplier financing[15]. - Operating lease right-of-use asset and liability recorded was $786,697, reflecting new lease agreements[15]. - Interest paid in 2025 was $187,389, indicating ongoing financing costs[15]. Research and Development - Research and development expenses decreased to $9.2 million for the fiscal year 2025, down from $11.9 million in 2024, while general and administrative expenses slightly increased to $18.5 million from $18.2 million[6]. - Citius is actively engaging with the FDA to advance Mino-Lok and explore additional indications and markets for LYMPHIR[2]. Product Launch and Market Access - Citius Oncology launched LYMPHIR™, a novel immunotherapy for cutaneous T-cell lymphoma, in December 2025, with an estimated initial market exceeding $400 million[3][5]. - Citius secured access to LYMPHIR in 19 international markets through regional distribution partners, allowing access under named patient programs[3]. - The company executed service agreements with three leading U.S. pharmaceutical wholesalers to distribute LYMPHIR throughout the U.S.[3]. - Citius ensured production and sufficient supply of LYMPHIR for up to 18 months of estimated commercial demand[3]. Assets and Financial Position - The total assets of Citius Pharmaceuticals increased to $130.9 million as of September 30, 2025, compared to $116.7 million in 2024[11].

Group 1 - The article does not provide any relevant content regarding the company or industry [1]

Fiscal Full Year 2025 Financial Highlights About Citius Oncology, Inc. Launched LYMPHIRâ"¢ (denileukin diftitox-cxdl), a novel IL2 receptor-directed immunotherapy, in the U.S. in December 2025 for the treatment of adult patients with relapsed or refractory Stage I–III cutaneous Tcell lymphoma (CTCL) after at least one prior systemic therapy; Executed service agreements with the three leading U.S. pharmaceutical wholesalers to distribute LYMPHIR to healthcare organizations, including major medical centers an ...

Subsidiary, Citius Oncology, launches cancer immunotherapy, LYMPHIRâ"¢, in the U.S. in December 2025 CRANFORD, N.J., Dec. 23, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal year ended September 30, 2025. "2025 was a pivotal year for Citius as we successfully launched LYMPHIR f ...

Product Development and Launch - Citius Pharmaceuticals launched LYMPHIR in December 2025, marking its transition to a commercial company[26] - The company is developing three proprietary products: Mino-Lok, Halo-Lido, and NoveCite, focusing on unmet medical needs in critical care[27] - Citius Pharma has paused most development initiatives for NoveCite to prioritize other product candidates, including LYMPHIR[138] - Citius Pharma plans to submit a New Drug Application (NDA) based on the positive outcomes from the Phase 3 trial and ongoing discussions with the FDA[97] Clinical Trial Results - LYMPHIR achieved a 36.2% overall response rate (ORR) in a pivotal trial with 69 patients, with 8.7% achieving a complete response[37][44] - The median duration of response for LYMPHIR was 6.5 months, with a median time to response of 1.4 months[38][44] - LYMPHIR demonstrated an overall response rate (ORR) of 27% (4 out of 15 patients) and a clinical benefit rate of 33% (5 out of 15 patients) among evaluable participants[58] - The median progression-free survival (PFS) for patients achieving clinical benefit was 57 weeks, with a range of 30 to 96 weeks[58] - The trial enrolled 21 patients with recurrent or metastatic solid tumors, with one patient showing durable stable disease lasting over six months[59] - The combination regimen of LYMPHIR and pembrolizumab was generally well tolerated, with only one case of dose-limiting toxicity (capillary leak syndrome) reported at the highest dose level of 12 mcg/kg[61] - The Phase 2b study of Halo-Lido showed that 42% of patients in the high dose CITI-002 group reached the meaningful change threshold (MCT) compared to 29% for high dose halobetasol alone and 21% for lidocaine alone[123] - The Phase 2a study of Halo-Lido demonstrated symptom improvement in hemorrhoids, with combination products showing favorable results compared to placebo[113] Market Potential and Financials - The addressable U.S. market for LYMPHIR is estimated to exceed $400 million, with potential for expansion with new therapeutic introductions[76] - The potential market for Mino-Lok in the U.S. is estimated to be approximately $500 million to $1 billion based on a target price of up to $400 per dose of each salvage flush treatment[106] - There are approximately 472,000 catheter-related bloodstream infections (CRBSIs) annually in the U.S., with an associated mortality rate of 12% to 35% and an attributable cost of $35,000 to $56,000 per episode[104] - Citius Pharma has a milestone payment obligation of $5.9 million to Eisai upon initial FDA approval of LYMPHIR, with additional payments tied to sales thresholds[149] - A $27.5 million milestone payment became due upon FDA approval for LYMPHIR, with a remaining balance of $19.75 million as of September 30, 2025[158] Regulatory and Compliance - The FDA required a new clinical study for LYMPHIR due to substantial manufacturing formulation improvements compared to the previously approved ONTAK[35] - The FDA issued a complete response letter (CRL) in July 2023, requiring enhanced product testing and additional controls, but did not raise concerns regarding safety and efficacy[70] - The FDA accepted the resubmission of the Biologics License Application (BLA) for LYMPHIR in March 2024, with a PDUFA goal date set for August 13, 2024[72] - The FDA granted Fast Track designation to Mino-Lok, expediting its review process due to its potential to treat a serious condition with unmet medical needs[98] - The FDA requires substantial time and financial resources for marketing approval, including extensive testing and compliance with cGMP regulations[201] - Post-approval, the FDA continues to regulate drugs, including requirements for recordkeeping and reporting of adverse experiences[206] Competitive Landscape - Citius Pharma has faced common pharmaceutical industry risks, including competition and dependence on key personnel[28] - Citius Oncology faces significant competition from established pharmaceutical companies and research institutions in the development of its drug candidates[179] - Mino-Lok is currently the only product approved for the treatment of infected central venous catheters (CVCs) in patients with CRBSI/CLABSI[181] - Halo-Lido, if approved, would be the only prescription product for the treatment of hemorrhoids, competing against non-prescription OTC products[187] Intellectual Property and Agreements - Citius Pharma acquired patents related to LYMPHIR, including methods of use with PD-1 pathway inhibitors, enhancing its competitive position in the market[159] - The stability patent for Mino-Lok enhances its intellectual property protection until November 2036, allowing for longer storage of the ready-to-use solution[101] - The license agreement with Eisai allows for a potential extension of 10 years after the first commercial sale, expected in December 2025[152] - NoveCite is obligated to pay up to $51 million in milestone payments and royalties based on net sales for the stem cell therapy developed under its license agreement[171] Distribution and Commercialization - Citius Pharma has entered into distribution agreements with Cardinal Health, Cencora, and McKesson Corporation to support the launch of LYMPHIR[144] - The company has developed a dedicated field force through a third-party commercial sales organization to facilitate the launch of LYMPHIR[143] - The commercial success of the company's product candidates will depend on governmental authorities and third-party payers providing adequate coverage and reimbursement levels, which are increasingly being restricted[211] Healthcare Environment and Challenges - The Affordable Care Act (ACA) has significantly impacted the pharmaceutical industry by broadening access to health insurance and imposing new taxes and fees on manufacturers[216] - Legislative changes have reduced Medicare payments to various healthcare providers, which could decrease utilization and reimbursement for the company's products[218] - The Inflation Reduction Act of 2022 includes provisions to lower prescription drug costs for Medicare patients, potentially affecting the company's business[219] - Future healthcare reform measures could limit government payments for healthcare products and services, resulting in reduced demand for the company's products[221]

Core Insights - Citius Oncology has entered an exclusive distribution agreement with Er-Kim for LYMPHIR, expanding its access to patients with cutaneous T-cell lymphoma in Turkey and key Gulf Cooperation Council (GCC) countries [1][3] - The partnership increases Citius Oncology's international strategy to a total of 19 markets outside the U.S., leveraging Named Patient Programs for access [2] - LYMPHIR is a targeted immune therapy approved by the FDA for adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma after at least one prior systemic therapy [5][9] Company Overview - Citius Oncology, a subsidiary of Citius Pharmaceuticals, focuses on developing and commercializing novel targeted oncology therapies, with LYMPHIR being a significant addition to its portfolio [9][10] - The initial market for LYMPHIR is estimated to exceed $400 million, indicating a growing and underserved market for this therapy [9] - Citius Pharmaceuticals holds a 79% stake in Citius Oncology and is dedicated to critical care product development [10] Product Details - LYMPHIR (denileukin diftitox-cxdl) is a recombinant fusion protein that targets IL-2 receptors, leading to cell death in tumors expressing these receptors [5] - The therapy has shown the ability to deplete immunosuppressive regulatory T lymphocytes and has direct antitumor activity [5] - LYMPHIR was launched in the U.S. in December 2025 after receiving FDA approval [6] Partnership Significance - The agreement with Er-Kim is viewed as a significant milestone in Citius Oncology's global expansion strategy, leveraging Er-Kim's industry experience and regulatory capabilities [3][4] - Er-Kim will handle sales, marketing, and reimbursement activities in the designated territories, while Citius Oncology will supply the finished product [3] Market Context - Cutaneous T-cell lymphoma is the most common type of cutaneous lymphoma, affecting men more frequently and typically diagnosed in individuals aged 50 to 60 [7][8] - There is currently no curative therapy for advanced CTCL, making innovative treatments like LYMPHIR critical for patient care [8]

Core Insights - Citius Oncology has launched LYMPHIR, a novel treatment for relapsed or refractory Stage I–III cutaneous T-cell lymphoma (CTCL), which has been approved by the FDA [1][11] - The product is expected to address a significant clinical need in a market valued at over $400 million, with potential for international expansion and additional indications [2][13] Product Overview - LYMPHIR (denileukin diftitox-cxdl) is a targeted immune therapy that combines the IL-2 receptor binding domain with diphtheria toxin fragments, specifically designed to treat CTCL after at least one prior systemic therapy [10][16] - The FDA approval was based on Pivotal Study 302, which showed an Objective Response Rate (ORR) of 36.2% and a median time to response of 1.4 months [3][11] Clinical Benefits - LYMPHIR offers rapid skin relief and has shown meaningful activity against severe pruritus, a common issue for CTCL patients [2][4] - The treatment is noted for its lack of cumulative toxicity, making it a compelling option for patients and physicians [4][10] Market Potential - The U.S. market for LYMPHIR is estimated to exceed $400 million and is expected to grow, indicating a strong demand for effective CTCL therapies [2][13] - Citius Oncology has exclusive rights to develop and commercialize LYMPHIR in all global markets except India, Japan, and certain parts of Asia, with plans for international distribution [7][11] Commercial Strategy - LYMPHIR is available through specialty distributors in the U.S., with a dedicated portal for healthcare providers to access treatment resources [5][9] - The launch is supported by medical education and payer access programs, and LYMPHIR has been included in the National Comprehensive Cancer Network (NCCN) Guidelines for CTCL [6][7] Company Background - Citius Oncology is focused on developing and commercializing novel targeted oncology therapies, with LYMPHIR being its first marketed product [13][14] - The company has robust intellectual property protections and is actively engaged in expanding its market presence [13][14]

Core Insights - Citius Oncology is set to showcase its novel immunotherapy LYMPHIR at the 67th American Society of Hematology Annual Meeting in December 2025, highlighting its potential as a treatment option for cutaneous T-cell lymphoma [1][3][2] Company Overview - Citius Oncology, a subsidiary of Citius Pharmaceuticals, focuses on developing targeted oncology therapies, with LYMPHIR being its primary asset approved by the FDA in August 2024 for relapsed or refractory Stage I–III cutaneous T-cell lymphoma [8][9] - The initial market for LYMPHIR is estimated to exceed $400 million and is considered underserved by existing therapies, supported by robust intellectual property protections [8] Product Details - LYMPHIR (denileukin diftitox-cxdl) is a targeted immune therapy that combines IL-2 receptor binding with diphtheria toxin fragments, specifically designed to treat adult patients with relapsed or refractory cutaneous T-cell lymphoma after at least one prior systemic therapy [4][10] - The drug has shown the ability to deplete immunosuppressive regulatory T lymphocytes and exhibit antitumor activity [4] Market Context - Cutaneous T-cell lymphoma is the most common type of cutaneous lymphoma, affecting men more frequently than women, typically diagnosed in individuals aged 50 to 60 [6] - The disease can progress slowly, with advanced stages leading to poor prognosis, highlighting the need for effective treatment options [6] Regulatory Milestones - LYMPHIR received regulatory approval in Japan in 2021 for similar indications and was subsequently licensed by Citius for development and commercialization in all markets except India, Japan, and certain parts of Asia [5]